Viewing Study NCT05355051


Ignite Creation Date: 2025-12-24 @ 11:52 PM
Ignite Modification Date: 2025-12-25 @ 9:47 PM
Study NCT ID: NCT05355051
Status: RECRUITING
Last Update Posted: 2025-10-24
First Post: 2022-04-25
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module